Aspire Biopharma
- Company typePublic
- Founded2021
- HeadquartersSan Juan, Puerto Rico
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Aspire Biopharma does
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a publicly traded biopharmaceutical and consumer products company built around a proprietary sublingual powder drug delivery platform designed to enable active pharmaceutical ingredients to be absorbed through the oral mucosa, bypassing the gastrointestinal tract and first-pass hepatic metabolism for rapid onset. The platform is protected by multiple pending patent applications (USPTO 63/456,290 and 63/702,381 covering micelle-based high-dose aspirin, an omnibus application filed October 2025, and provisional patents filed January and February 2026 covering alprazolam, ondansetron, and meclizine) and a trade-secret formulation process. The company's lead pharmaceutical candidate, OTASA, is a 162.5 mg sublingual aspirin powder for emergency treatment of suspected acute myocardial infarction, which has completed Phase 1 clinical trials with positive results and received a successful FDA Type B pre-IND meeting supporting a 505(b)(2) filing targeted in H2 2026.
The company generates minimal revenue from a single launched consumer product, BUZZ BOMB, a 50 mg sublingual caffeine stick pack sold via direct e-commerce (buzzbomb.buzz), Amazon, and a network of US distribution partners including TruLife Distribution (national retail), Blue Shark Beverages (Southern California), Interwest Brokerage (Utah/Idaho/Montana), and EoS Fitness (225+ gym locations). Trailing twelve-month revenue is approximately $30,000 as of mid-2026, with BUZZ BOMB only launched in mid-2025. The company also has a pipeline of additional sublingual candidates including alprazolam (in partnership with Microsize with Phase 1 planned mid-2026), meclizine, ondansetron, semaglutide, and an ED medication.
The business model is in transition. Beyond BUZZ BOMB consumer sales and future pharmaceutical prescription sales and licensing royalties, the company signed a definitive agreement in June 2026 to acquire Dura Driver Control Systems (DCS), a tier-one automotive supplier with over $200 million in revenue and $22 million in Adjusted EBITDA for FY2025, for $30 million in cash, with closing expected in Q3 2026. Financing includes a $21M private placement of Series A Convertible Preferred Stock completed in April 2026 and a $22.5M senior secured credit facility commitment letter. The company is headquartered in Estero, Florida (relocated from Humacao, Puerto Rico), was founded in 2021, employs 11-50 people, and went public in February 2025 via a business combination with PowerUp Acquisition Corp.
Aspire Biopharma firmographics
Firmographics- Name
- Aspire Biopharma
- Legal name
- Aspire Biopharma Holdings Inc.
- Website
- https://aspirebiolabs.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Aspire Biopharma industry classification
Industry- Product category
- Sublingual Pharmaceutical Drug Delivery
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industries
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Functional Foods & Supplement Formats (Gummies, Chews, Powders, Shots) (CRADAGAI)
Keywords
Where Aspire Biopharma is headquartered
LocationHeadquarters
- HQ city
- San Juan
- HQ country
- Puerto Rico
- HQ region
- Latin America
Offices2 records
Markets served
Aspire Biopharma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- BUZZ BOMB product sales: Direct sales of BUZZ BOMB energy drink products via company-owned e-commerce (buzzbomb.buzz), Amazon marketplace, and a growing network of distribution partners across the United States. One-time transactional purchases with no recurring subscription model described.
- Planned prescription product sales: Future prescription sales of sublingual Aspirin and other pharmaceutical products entering the prescription market beginning in 2026, representing a shift to regulated pharmaceutical revenue.
- Technology licensing: Future licensing of sublingual drug delivery technology to other pharmaceutical companies, generating licensing royalties on licensed applications.
Go-to-market motion4 records
Distribution channels7 records
Marketing channels7 records
Aspire Biopharma product offering
Product offeringCore offering
Aspire Biopharma develops and commercializes a proprietary sublingual powder drug delivery platform that enables active pharmaceutical ingredients and supplements to be absorbed through the oral mucosa, bypassing the gastrointestinal tract and first-pass hepatic metabolism for rapid onset of action. The company currently markets the BUZZ BOMB consumer caffeine supplement (50mg sublingual stick packs in multiple flavors) via direct-to-consumer e-commerce and Amazon, and is developing pharmaceutical products led by sublingual aspirin (OTASA) for emergency cardiac care, with a pipeline spanning alprazolam, ondansetron, meclizine, semaglutide, and erectile dysfunction medications.
Product overview
Aspire Biopharma's offering centers on a proprietary, patent-pending sublingual drug and supplement delivery technology platform (the Aspire Targeted Oral Delivery Platform) that enables rapid absorption of active ingredients under the tongue, bypassing the gastrointestinal tract and first-pass hepatic metabolism. Built on this platform, the company is advancing both pharmaceutical and consumer health products. The lead pharmaceutical product, Sublingual Aspirin (OTASA), is a fast-acting 162.5 mg high-dose aspirin powder developed for emergency treatment of suspected acute myocardial infarction (heart attack) and for pain management. Through its wholly owned subsidiary Buzz Bomb Caffeine Company, the company markets BUZZ BOMB, a 50 mg sublingual caffeine stick pack consumer supplement (with a dedicated channel-specific BUZZ BOMB Convenience Store Pack variant) sold across e-commerce (buzzbomb.buzz), fitness, convenience, and grocery channels. Pipeline candidates being advanced on the same platform include Sublingual Alprazolam (anxiety, in partnership with Microsize), Sublingual Meclizine (motion sickness / vertigo), Sublingual Ondansetron (chemotherapy-induced nausea), Sublingual Semaglutide (diabetes / weight management), and a Sublingual Erectile Dysfunction (ED) medication, with additional indications such as clopidogrel and other drugs under exploration.
Differentiator
Problem solved
Functional benefit
Brands
- BUZZ BOMB: 50mg sublingual caffeine stick pack supplement in multiple flavors (Tropical Fruit, Mixed Berry, Peach Mango, Coffee Mocha, Watermelon, Lemon Lime), positioned as a fast-onset alternative to energy drinks and pre-workout mixes; operated by wholly owned subsidiary Buzz Bomb Caffeine Company LC.
- OTASA
Products and services
- BUZZ BOMB A 50mg sublingual caffeine stick pack delivered as a single-serving dry powder that dissolves under the tongue without water, marketed as a rapid-onset, clean alternative to traditional energy drinks and pre-workout products. Sold in multiple flavors (Tropical Fruit, Mixed Berry, Peach Mango, Coffee Mocha) through e-commerce, fitness, convenience, and grocery channels.
- BUZZ BOMB Convenience Store Pack A convenience-store-formatted pack of BUZZ BOMB dry powder caffeine stick packs, designed as single-serving sticks for on-the-go consumption and targeted at c-store distribution.
Quantifiable outcome
- Sublingual delivery bypasses first-pass metabolism for improved bioavailability versus oral formulations.
- +2 more outcomes
Companies that use Aspire Biopharma
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles3 records
Aspire Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aspire Biopharma partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core, minor and flagship.
- EoS FitnesscorePartnership to make BUZZ BOMB available at EoS Fitness gym chain locations, providing direct consumer access to fitness enthusiasts; announced May 27, 2026.
- Interwest BrokerageminorSales and marketing brokerage covering Utah, Idaho, and Montana retail markets; agreement announced April 15, 2026.
- TruLife DistributioncoreNational retail distribution agreement for BUZZ BOMB consumer products; announced March 19, 2026.
- MicrosizecoreCo-development partner for sublingual alprazolam formulation; partnership announced March 3, 2026.
- Blue Shark BeveragesminorDistribution agreement covering the Southern California territory for BUZZ BOMB consumer products; announced February 3, 2026.
- Glatt Air Techniques, Inc.flagshipPharmaceutical development partner supporting formulation, scale-up, and manufacturing of Aspire's sublingual drug products. Engagement announced July 2022.
- ParexelcoreContract Research Organization (CRO) supporting Aspire's clinical trial activities across its sublingual pharmaceutical pipeline.
- PacecoreTesting and analytical laboratory partner supporting alprazolam formulation development and quality testing.
- SupraNaturalscoreContract manufacturing partner for BUZZ BOMB consumer products.
- Desert StreamminorInitial production manufacturer used for early BUZZ BOMB production runs.
- CTM Advisory, Ltd.minorAdvisory engagement supporting the business combination transaction and merger advisory.
- Spartan Capital Securities, LLCminorAdvisory engagement supporting the business combination transaction and merger advisory.
- PowerUp Acquisition Corp.flagshipSpecial purpose acquisition company (SPAC) partner that took Aspire Biopharma public via business combination in 2024.
- Lakewood & CompanycoreManagement support firm providing ongoing operational and management services to Aspire Biopharma.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Aspire Biopharma competitors and assessment
Company assessmentDirect peers
- Aquestive Therapeutics: Commercial-stage specialty pharma focused on sublingual drug delivery using proprietary PharmFilm technology. Direct comparable to Aspire on sublingual platform approach and multi-drug pipeline, with multiple FDA-approved products (Suboxone, Exservan, Zuplenz).
- IntelGenx Corp: Sublingual and oral transmucosal drug delivery company with VersaFilm technology, targeting similar reformulation plays across multiple drug classes. Closely comparable on platform-leverage strategy.
- Evoke Pharma: Specialty pharma developing Gimoti, a nasal-delivery alternative for metoclopramide in gastroparesis — overlaps with Aspire's antiemetic (ondansetron) and GI pipeline addressing nausea and vomiting when oral dosing fails.
- Living Essentials (5-hour Energy): Direct competitor to BUZZ BOMB in the rapid-onset, single-serve caffeine/energy category. Closest format comparable for the consumer supplement business.
Broad incumbents
- Celsius Holdings: Major energy drink and fitness-oriented beverage incumbent with broad retail distribution. Comparable to BUZZ BOMB on target consumer (fitness enthusiasts) and shelf placement in convenience, fitness, and grocery channels.
- Tris Pharma: Specialty pharma with liquid and orally-disintegrating-tablet drug delivery capabilities, pursuing the 505(b)(2) regulatory pathway. Comparable to Aspire on reformulation strategy and regulatory approach.
- ANI Pharmaceuticals: Specialty generic pharma active in the 505(b)(2) pathway, with a focus on reformulating established molecules for new indications or delivery formats — analogous to Aspire's pipeline strategy.
- Pfizer: Manufacturer of branded aspirin and a global pharmaceutical incumbent. Represents the established player whose cardiovascular and analgesic franchises OTASA would partially compete with or partner around.
- Bayer AG: Global pharmaceutical and consumer health incumbent with the Aspirin brand. Represents an obvious potential acquirer or licensing partner for a faster-onset sublingual aspirin product addressing the same underlying market.
Emerging players
- Alani Nutrition: Fast-growing pre-workout and energy supplement brand targeting female fitness consumers — adjacent competitor to BUZZ BOMB in the pre-workout/supplement category with strong social media positioning.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Aspire Biopharma social profiles
Digital presenceAspire Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspire Biopharma leadership team
Management profileNumber of profiles
Profiles7 records
Aspire Biopharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aspire Biopharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspire Biopharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspire Biopharma
What does Aspire Biopharma do?
Aspire Biopharma develops and commercializes a proprietary sublingual powder drug delivery platform that enables active pharmaceutical ingredients and supplements to be absorbed through the oral mucosa, bypassing the gastrointestinal tract and first-pass hepatic metabolism for rapid onset of action. The company currently markets the BUZZ BOMB consumer caffeine supplement (50mg sublingual stick packs in multiple flavors) via direct-to-consumer e-commerce and Amazon, and is developing pharmaceutical products led by sublingual aspirin (OTASA) for emergency cardiac care, with a pipeline spanning alprazolam, ondansetron, meclizine, semaglutide, and erectile dysfunction medications.
Is Aspire Biopharma a public or private company?
Aspire Biopharma is a public company. It is classified as public and is currently operating.
When was Aspire Biopharma founded?
Aspire Biopharma was founded in 2021. It employs 11 to 50 people.
Where is Aspire Biopharma based?
Aspire Biopharma is headquartered in San Juan, Puerto Rico, in the Latin America region.
How does Aspire Biopharma make money?
Three revenue lines are on record. BUZZ BOMB product sales are the primary driver. The others are planned prescription product sales and technology licensing.
Who are Aspire Biopharma's main competitors?
Direct peers on record are Aquestive Therapeutics, IntelGenx Corp, Evoke Pharma and Living Essentials (5-hour Energy). Broad incumbents are Celsius Holdings, Tris Pharma, ANI Pharmaceuticals, Pfizer and Bayer AG. Alani Nutrition is listed as an emerging player.
Does Aspire Biopharma have an API?
No public API is recorded for Aspire Biopharma.
What industry is Aspire Biopharma in?
Aspire Biopharma's product category is Sublingual Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.